Back to Clinical Trials
Early Phase 1Recruiting

Effect of Neural Constraints on Movement in Stroke

Sponsored by Northwestern University

About this study

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Sixty-four individuals with stroke will be recruited. Efforts will be made to recruit the same participants for each protocol. A REDCap database for this study will be setup to manage every step involved in the protocol. The experiment uses a two-arm, cross-over, double-blinded, pre-test-post-test, randomized controlled design. After confirming eligibility, all enrolled participants will be scheduled for one anatomic brain MRI data collection and 6 arm/ hand experiments: 2 for each aim, one with TIZ and the other with placebo. All experiments will take place on separate days at least one week apart. During each of the experimental sessions, the participant will complete the protocol both before and 1.5 hours after administration of either TIZ or a placebo. The order of using TIZ or a plac…

Where this study is enrolling

  • Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100

    Chicago, Illinois

    I'm interested
Who can participate

Inclusion criteria

  • ✓History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
  • ✓Age between 18-80
  • ✓Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66)
  • ✓Ability to communicate, understand, and provide informed consent
  • ✓Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension
  • ✓MRI compatible
  • ✓Intact skin on the hemiparetic arm
  • ✓Ability to sit for three hours.

Exclusion criteria

  • ✕Motor or sensory impairment in the non-affected limb (FMA\<66, filament \>3.6)
  • ✕Any brainstem and/or cerebellar lesion
  • ✕untreated cardiovascular disease
  • ✕History of neurologic disorder other than stroke that affects the arms
  • ✕Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • ✕Current use of a pacemaker
  • ✕History of seizure
  • ✕Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation
  • ✕Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes
  • ✕Current participation in any experimental rehabilitation or drug studies
  • ✕Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity
  • ✕pregnant women or women who are nursing.
  • ✕Additionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in "Medication Interactions", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive/ antiarrhythmic agents; and hormonal medications/contraceptives.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.